The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Detection of free‐circulating tumor‐associated DNA in plasma of colorectal cancer patients and its association with prognosis
Open accessAbstract
Tumor cells are characterized by specific genetic alterations. When such genetic alterations are identified in body fluid including plasma, regardless of the presence of detectable tumor cells, it shows the existence of free‐circulating tumor‐associated DNA. The objective of our study was to assess the prognostic value of free‐circulating tumor‐associated DNA in colorectal cancer patients' plasma. The first step of our work was to find common genetic alterations in tumors that would subsequently be used for plasma DNA screening. We focused on KRAS2 mutations in codons 12 and 13 by the mutant allele‐specific amplification (MASA) method and p16 hypermethylation by the methylation‐specific polymerase chain reaction (MSP) method. Patients with a tumor presenting either alteration were selected for plasma screening; 58 tumors were analyzed for KRAS2 mutations and tested for p16 gene promoter methylation. Survival and recurrence rates were assessed in patients with and without free‐circulating tumor‐associated DNA alterations in plasma. Of the 58 tumors analyzed, 39 (67%) demonstrated either one or both of the studied genetic alterations. Twenty‐two (38%) were mutated at KRAS2, and an identical alteration was detected in 10 (45%) of the 22 corresponding plasma samples. Thirty‐one (53%) had p16 gene promoter hypermethylation that could also be detected in the plasma in 21 cases (68%). Among the 39 patients who had one or the other alteration in tumor DNA, 37 had at least one reliable plasma test. In 26 (70%) of the 37 patients, free‐circulating tumor‐associated DNA was detected in plasma. The 2‐year overall survival rate was 48% in the group where free‐circulating tumor‐associated DNA was detected in plasma and 100% in the one where free‐circulating tumor‐associated DNA was not detected in plasma (p< 0.03). Among these 37 patients, 25 patients had a stage I, II or III disease. In this subgroup of patients, the 2‐year recurrence‐free survival rate for the 17 patients with free‐circulating tumor‐associated DNA detected in plasma was 66%, compared to 100% for the 8 patients without free‐circulating tumor‐associated DNA detected in plasma (p= 0.044). The presence of free‐circulating tumor‐associated DNA in plasma seems to be a relevant prognostic marker for patients with colorectal cancer and may be used to identify patients with a high risk of recurrence. © 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728
TNM Classification of Malignant Tumors
Carter, D. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199810000-00016 · Cited by 6,330
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
Herman, J. G., Graff, J. R., Myöhänen, S., Nelkin, B. D., & Baylin, S. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9821 · Cited by 5,646
Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma
Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Goodman, P. J., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002083220602 · Cited by 2,256
Spiess, P. E., Lee, A. K., Leibovici, D., Wang, X., Do, K., & Pisters, L. L. (2006) · Cancer · doi:10.1002/cncr.21979 · Cited by 1,930
(1977) · PubMed · Cited by 1,801
Herman, J. G., Merlo, A. U., Mao, L., Lapidus, R. G., Issa, J. J., Davidson, N. E., Sidransky, D., & Baylin, S. B. (1995) · PubMed · Cited by 1,341
Cited by
Cell-free nucleic acids as biomarkers in cancer patients
Schwarzenbach, H., Hoon, D. S. B., & Pantel, K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3066 · Cited by 2,891
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809
The power and the promise of DNA methylation markers
Laird, P. W. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1045 · Cited by 1,562
Epigenetics of colorectal cancer: biomarker and therapeutic potential
Jung, G., Hernández-Illán, E., Moreira, L., Balaguer, F., & Goel, A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0230-y · Cited by 813
Circulating nucleic acids (CNAs) and cancer—A survey
Fleischhacker, M., & Schmidt, B. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.10.001 · Cited by 851
Circulating Tumor DNA as a Liquid Biopsy for Cancer
Heitzer, E., Ulz, P., & Geigl, J. B. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.222679 · Cited by 767
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
Thierry, A. R., Mouliere, F., El Messaoudi, S., Mollevi, C., Lopez-Crapez, E., Rolet, F., Gillet, B., Gongora, C., Dechelotte, P., Robert, B., et al. (2014) · Nature Medicine · doi:10.1038/nm.3511 · Cited by 678
The emerging role of cell-free DNA as a molecular marker for cancer management
Bronkhorst, A. J., Ungerer, V., & Holdenrieder, S. (2019) · Biomolecular Detection and Quantification · doi:10.1016/j.bdq.2019.100087 · Cited by 566
Next-generation sequencing in liquid biopsy: cancer screening and early detection
Chen, M., & Zhao, H. (2019) · Human Genomics · doi:10.1186/s40246-019-0220-8 · Cited by 556
Quantitative and sensitive detection of rare mutations using droplet-based microfluidics
Pekin, D., Skhiri, Y., Baret, J.-C., Le Corre, D., Mazutis, L., Ben Salem, C., Millot, F., El Harrak, A., Hutchison, J. B., Larson, J. W., et al. (2011) · Lab on a Chip · doi:10.1039/c1lc20128j · Cited by 540
Self-citationTaly, V., Pekin, D., Benhaim, L., Kotsopoulos, S. K., Le Corre, D., Li, X., Atochin, I., Link, D. R., Griffiths, A. D., Pallier, K., et al. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.206359 · Cited by 492
Self-citationGormally, E., Caboux, E., Vineis, P., & Hainaut, P. (2007) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2006.11.002 · Cited by 445
Ignatiadis, M., Lee, M., & Jeffrey, S. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1190 · Cited by 355
Cell-free DNA in the blood as a solid tumor biomarker–a critical appraisal of the literature
Jung, K., Fleischhacker, M., & Rabien, A. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.07.032 · Cited by 337
van der Pol, Y., & Mouliere, F. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.003 · Cited by 324
Song, P., Wu, L. R., Yan, Y. H., Zhang, J. X., Chu, T., Kwong, L. N., Patel, A. A., & Zhang, D. Y. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00837-3 · Cited by 319
Gorgannezhad, L., Umer, M., Islam, M. N., Nguyen, N.-T., & Shiddiky, M. J. A. (2018) · Lab on a Chip · doi:10.1039/c8lc00100f · Cited by 312
Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis
Herceg, Z., & Hainaut, P. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.01.004 · Cited by 282
Circulating biomarkers for early detection and clinical management of colorectal cancer
Marcuello, M., Vymetalkova, V., Neves, R. P. L., Duran-Sanchon, S., Vedeld, H. M., Tham, E., van Dalum, G., Flügen, G., Garcia-Barberan, V., Fijneman, R. J., et al. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.06.002 · Cited by 275
Shulman, D. S., Klega, K., Imamovic-Tuco, A., Clapp, A., Nag, A., Thorner, A. R., Van Allen, E., Ha, G., Lessnick, S. L., Gorlick, R., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0212-9 · Cited by 149
Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies
Abbou, S. D., Shulman, D. S., DuBois, S. G., & Crompton, B. D. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27595 · Cited by 72
Mimori, K., Fukagawa, T., Kosaka, Y., Kita, Y., Ishikawa, K., Etoh, T., Iinuma, H., Sasako, M., & Mori, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4354 · Cited by 71
Metadata
- Authors
- Lecomte, T., Berger, A., Zinzindohoué, F., Micard, S., Landi, B., Blons, H., Beaune, P., Cugnenc, P., & Laurent‐Puig, P.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2002-07-17
- Volume
- 100
- Issue
- 5
- Pages
- 542-548
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2023071984
- Cited by
- 292
- References
- 48
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.